News & Updates

Apathy may have a significant impact on cognitive health of stroke survivors, according to results of a cross-sectional study by the Chinese University of Hong Kong.

An intranasally administered recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life (neuroEPO) restores cognitive function or delays progression in most patients with mild-to-moderate Alzheimer’s disease, results of the phase II/III double-blind, placebo-controlled ATHENEA trial have shown.

Adding subcutaneous daratumumab to the three-drug regimen containing bortezomib, lenalidomide, and dexamethasone (VRd) appears to improve outcomes for transplant-eligible patients with newly diagnosed multiple myeloma (MM), with extended disease-free periods and increased depth of response, according to the phase III PERSEUS trial.